Alnylam Pharmace. buy JPMorgan Chase & Co.
Start price
12.06.25
/
50%
€264.00
Target price
12.06.26
€296.26
Performance (%)
6.59%
Price
18:41
€290.50
Summary
This prediction is currently active. With a performance of 6.59%, the BUY prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 12.06.26. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -0.211% | -0.211% |
| iShares Core DAX® | 3,02 % | 2,20 % |
| iShares Nasdaq 100 | 3,56 % | 1,33 % |
| iShares Nikkei 225® | 6,62 % | 5,71 % |
| iShares S&P 500 | 2,64 % | 1,01 % |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at JPMorgan Chase & Co. from $330.00 to $338.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€406.80
13.10.25
13.10.25
€407.06
13.10.26
13.10.26
-28.86%
18:41
18:41
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€270.10
24.03.25
24.03.25
€302.97
24.03.26
24.03.26
-3.00%
25.03.26
25.03.26